Loading…
Utah Medical Products, Inc. is projected to rise to $78.94 by 2027, a +12% move from its current price of $70.52. UTMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $69.15 | $70.53 | $71.95 | +0.02% |
| Aug 4 | $68.59 | $70.55 | $72.56 | +0.04% |
| Aug 5 | $68.18 | $70.56 | $73.03 | +0.06% |
| Aug 6 | $67.83 | $70.58 | $73.44 | +0.08% |
| Aug 7 | $67.52 | $70.59 | $73.80 | +0.10% |
| Aug 8 | $67.25 | $70.60 | $74.13 | +0.12% |
| Aug 9 | $67.00 | $70.62 | $74.43 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $67.00 | $70.62 | $74.43 | +0.14% |
| Week 2 | $65.65 | $70.72 | $76.18 | +0.28% |
| Week 3 | $64.65 | $70.82 | $77.57 | +0.42% |
| Week 4 | $63.84 | $70.92 | $78.78 | +0.56% |
| Week 5 | $63.14 | $71.02 | $79.88 | +0.70% |
| Week 6 | $62.52 | $71.12 | $80.89 | +0.85% |
| Week 7 | $61.97 | $71.22 | $81.85 | +0.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Utah Medical Products, Inc. is a healthcare company that offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Its portfolio includes GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. It also offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures.
Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Utah Medical Products, Inc. (UTMD) is a healthcare company with a current price of $67.96 and a market cap of $216.39M. It is ranked 3620 by market capitalization. The stock carries a 2026 forecast average of $67.96, and shows a bullish trajectory through 2050, with the 2040 and 2050 averages at $257.07 and $492.49 respectively.
These figures indicate substantial upside potential over the longer horizon, though they are not guarantees. The forecast table shows year-by-year growth with rising averages and ROIs, culminating in an average of $492.49 for 2050 and a ROI of 624.7%.
A major floor 15.2% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 4.9% above — a clean break opens room to run.
A major ceiling 12.5% above — clearing it would confirm fresh momentum.
Key UTMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UTMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $70.22 | Buy | $69.92 | Buy |
| MA 10 | $69.01 | Buy | $69.55 | Buy |
| MA 20 | $69.29 | Buy | $69.28 | Buy |
| MA 50 | $68.25 | Buy | $68.34 | Buy |
| MA 100 | $66.68 | Buy | $66.81 | Buy |
| MA 200 | $63.19 | Buy | $64.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.65 | Neutral |
| Stoch RSI (14) | 81.01 | Sell |
| CCI (20) | 67.16 | Neutral |
| Williams %R (14) | -16.14 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 0.14 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 83.86 | Sell |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 1.16 | Buy |
| Ultimate (7,14,28) | 53.67 | Neutral |
| Momentum (10) | 0.72 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 71.26 | Sell |
| ADX (14) | 8.40 | Neutral |
| ATR (14) | 1.52 | Info |
The near-term technical picture is NEUTRAL with RSI14 at 50. The 50-day moving average is $66.80 and the 200-day moving average is $62.70. Support sits at $65.21 and resistance at $73.97, framing a 30-day price range of $60.36 to $76.52. The stock exhibits an annualized volatility of 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $56.50 | $70.52 | $91.35 | 0% | Neutral | |
| $64.52 | $78.94 | $101.08 | +12% | Neutral | |
| $76.45 | $95.43 | $125.72 | +35% | Bullish | |
| $87.73 | $111.32 | $149.96 | +58% | Bullish | |
| $100.65 | $129.55 | $177.85 | +84% | Bullish | |
| $112.65 | $146.89 | $205.01 | +108% | Bullish | |
| $118.62 | $156.54 | $221.74 | +122% | Bullish | |
| $125.68 | $167.73 | $240.82 | +138% | Bullish | |
| $128.77 | $173.68 | $252.49 | +146% | Bullish | |
| $137.81 | $187.74 | $276.11 | +166% | Bullish | |
| $209.02 | $297.85 | $460.03 | +322% | Bullish | |
| $391.75 | $601.70 | $999.08 | +753% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $56.50 | $70.52 | $86.45 | +0.00% |
| September 2026 | $61.58 | $72.27 | $86.80 | +2.49% |
| October 2026 | $60.90 | $71.82 | $86.94 | -0.62% |
| November 2026 | $62.25 | $73.70 | $89.79 | +2.62% |
| December 2026 | $62.73 | $74.56 | $91.35 | +1.16% |
Click any year to see its month-by-month UTMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, UTMD is projected to trade between $56.50 and $91.35, averaging $70.52 — a potential gain of 0% from today's $70.52. A consolidation phase looks the most probable path here.
Utah Medical Products, Inc.'s 2027 outlook centres on $78.94, within a $64.52 to $101.08 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, UTMD could reach as high as $125.72, with a base case around $95.43 and support toward $76.45 — roughly +35% from $70.52. Buyers look set to stay in control over this stretch.
Expect UTMD to range from $87.73 to $149.96 through 2029. The $111.32 average target implies a +58% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The UTMD price prediction for 2030 points to an average of $129.55 (low $100.65, high $177.85) — a potential gain of +84% on today's $70.52. Buyers look set to stay in control over this stretch.
In 2031, UTMD is projected to trade between $112.65 and $205.01, averaging $146.89 — a potential gain of +108% from today's $70.52. That is up +13% on the projected 2030 average. Momentum favours further upside here.
Utah Medical Products, Inc.'s 2032 outlook centres on $156.54, within a $118.62 to $221.74 range. That is up +7% on the projected 2031 average. That marks a +122% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, UTMD could reach as high as $240.82, with a base case around $167.73 and support toward $125.68 — roughly +138% from $70.52. Momentum favours further upside here.
Expect UTMD to range from $128.77 to $252.49 through 2034. The $173.68 average target implies a +146% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The UTMD price prediction for 2035 points to an average of $187.74 (low $137.81, high $276.11) — a potential gain of +166% on today's $70.52. Momentum favours further upside here.
In 2040, UTMD is projected to trade between $209.02 and $460.03, averaging $297.85 — a potential gain of +322% from today's $70.52. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Utah Medical Products, Inc.'s 2050 outlook centres on $601.70, within a $391.75 to $999.08 range. That is up +102% on the projected 2040 average. That marks a +753% change versus current levels. Momentum favours further upside here.
Investing $1,000 in UTMD today (≈ 14.180374 UTMD) could be worth
$8,532.4
+$7,532.4 (+753%) by 2050 · US Dollar
Based on the average projected UTMD price of $601.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UTMDwould be worth at today's price.
$1,000 invested in UTMD on Jul 31, 2025 (≈ 17.985612 UTMD) would be worth
$1,268.35
+$268.35 (+26.8%) today · 1.27× · US Dollar
Based on a UTMD entry price of $55.6 vs. today's $70.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $67.14 | $1,050.34 | +5.0% |
| 1 month ago | $70.63 | $998.44 | -0.2% |
| 3 months ago | $65.77 | $1,072.22 | +7.2% |
| 6 months ago | $61.76 | $1,141.84 | +14.2% |
| 1 year ago | $55.6 | $1,268.35 | +26.8% |
| All time (5.0y) ago | $87.51 | $805.85 | -19.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UTMD forecast.
Our base-case forecast reaches $140.00 around 2031.
Implied market cap at $140.00: $445.76M
The multi-year forecast points to a bullish path after a couple of neutral years. The 2030 average is $117.40 with a 72.8% ROI, the 2040 average is $257.07 with a 278.3% ROI, and the 2050 average is $492.49 with a 624.7% ROI. The forecast also shows sustained bullish sentiment from 2028 onward, with 2028 and later years labeled BULLISH.
These are estimates, not guarantees, and subject to market risk and volatility.
Tap a question to reveal the answer.
Avg $117.40; max $160.02; min $91.71; ROI 72.8%; sentiment BULLISH.
Forecast shows rising averages through 2040 and 2050 with bullish sentiment from 2028 onward; 2026 average is $67.96, 2027 $75.03, 2028 $90.33, 2029 $100.55, 2030 $117.40, and 2050 $492.49, but these are estimates, not guarantees.
Yes, the 2030 max is $160.02.
Avg $257.07; max $392.11; min $182.56; ROI 278.3%; sentiment BULLISH.
Avg $492.49; max $805.25; min $326.11; ROI 624.7%; sentiment BULLISH.
Utah Medical Products, Inc. Community Discussion
0Share your Utah Medical Products, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.